Table 1.
Histopathologic characteristics of the cases tested by NGS.
| Tumor site | Number | Percent |
|---|---|---|
| Ovary | 151 | 50.50% |
| Endometrium | 87 | 29.10% |
| Cervix | 27 | 9.03% |
| Peritoneum | 11 | 3.68% |
| Fallopian tube | 11 | 3.68% |
| Adnexa | 5 | 1.67% |
| Vulva | 2 | 0.67% |
| Vagina | 2 | 0.67% |
| Unknown | 3 | 1.00% |
| Tumor histotype | ||
| High grade serous | 157 | 52.51% |
| Endometrioid | 51 | 17.06% |
| Squamous cell carcinoma | 17 | 5.69% |
| Carcinosarcoma | 16 | 5.35% |
| Clear cell carcinoma | 11 | 3.68% |
| Low grade Serous | 8 | 2.68% |
| Cervical adenocarcinoma | 5 | 1.67% |
| Adenosarcoma | 3 | 1.00% |
| Adult granulosa cell tumor | 3 | 1.00% |
| Mucinous carcinoma | 3 | 1.00% |
| Borderline Serous | 2 | 0.67% |
| Dedifferentiated carcinoma | 2 | 0.67% |
| Sertoli-Leydig cell tumor | 2 | 0.67% |
| Endometrial stromal sarcoma | 1 | 0.33% |
| Leiomyosarcoma | 1 | 0.33% |
| Mucinous, borderline | 1 | 0.33% |
| Sero-mucinous | 1 | 0.33% |
| Others | 15 | 5.02% |
| Pathologic Tumor stage (pT) | ||
| pT1 | 28 | 9.60% |
| pT2 | 12 | 4.10% |
| pT3 | 54 | 18.60% |
| pT4 | 196 | 68.30% |